- Home
- MNOV vs ASRT Comparison
MNOV vs ASRT Comparison
Compare MNOV & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ASRT |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 76.0M |
| IPO Year | 2004 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MNOV | ASRT |
|---|---|---|
| Price | $1.46 | $13.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 73.0K | 45.0K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.13 | $0.51 |
| 52 Week High | $1.96 | $13.90 |
Technical Indicators
Market Signals| Indicator | MNOV | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 72.14 |
| Support Level | $1.24 | $0.69 |
| Resistance Level | $1.62 | N/A |
| Average True Range (ATR) | 0.08 | 0.68 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 61.42 | 98.27 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.